|Day Low/High||2.36 / 2.42|
|52 Wk Low/High||2.96 / 25.60|
Early signs of clinical activity without increased toxicity observed
Combination study with checkpoint inhibitor currently enrolling; data from combination arm with varlilumab anticipated in fall of 2017
Investors in Celldex Therapeutics, Inc. saw new options begin trading this week, for the November 17th expiration.
Conference Call Scheduled for 4:30 p.m. ET Today
Investors in Celldex Therapeutics, Inc. saw new options become available this week, for the March 17th expiration.
TheStreet's biotech columnist offers his own report card on biotech stocks.
A look back at the year's worth of Adam Feuerstein's biotech tweets.
Additional investigator-sponsored presentations on varlilumab, CDX-301 and CDX-1401 also at ASH
Investors considering a purchase of Celldex Therapeutics, Inc. shares, but cautious about paying the going market price of $4.17/share, might benefit from considering selling puts among the alternative strategies at their disposal.
The imbalances in patient baseline characteristics provided an assist to Corbus' resunab treatment response and undermines the credibility of the trial results, a source says.
--Conference call to be held at 4:30 p.m. Eastern Time today--
Combination study with checkpoint inhibitor planned; combination arm with varlilumab currently enrolling
Celldex Therapeutics (CLDX) reported a narrower loss than analysts had anticipated for the 2016 second quarter after Monday's closing bell.
Trade-Ideas LLC identified Celldex Therapeutics (CLDX) as a strong on high relative volume candidate
Conference Call Scheduled for Monday, August 8 at 4:30 p.m. Eastern Time